These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38332190)

  • 21. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
    Dingemanse J; van Giersbergen PL
    Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
    Angeli F; Verdecchia P; Reboldi G
    Cardiol Ther; 2021 Dec; 10(2):397-406. PubMed ID: 34251649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension.
    Tamargo J
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):371-373. PubMed ID: 38754980
    [No Abstract]   [Full Text] [Related]  

  • 24. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
    McCoy EK; Lisenby KM
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
    Krause A; Zisowsky J; Dingemanse J
    Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
    Danaietash P; Verweij P; Wang JG; Dresser G; Kantola I; Lawrence MK; Narkiewicz K; Schlaich M; Bellet M;
    J Clin Hypertens (Greenwich); 2022 Jul; 24(7):804-813. PubMed ID: 35686330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
    Heidari Nejad S; Azzam O; Schlaich MP
    Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.
    Nejad SH; Azzam O; Schlaich MP
    Future Cardiol; 2024 Jul; ():1-11. PubMed ID: 38953510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.
    Volz AK; Krause A; Haefeli WE; Dingemanse J; Lehr T
    Clin Pharmacokinet; 2017 Dec; 56(12):1499-1511. PubMed ID: 28401480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects.
    Soubret A; Pang Y; Yu J; Dahlke M
    Br J Clin Pharmacol; 2018 Nov; 84(11):2572-2585. PubMed ID: 30014598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
    Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
    Lalovic B; Majid O; Aluri J; Landry I; Moline M; Hussein Z
    J Clin Pharmacol; 2020 Dec; 60(12):1642-1654. PubMed ID: 32666570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
    Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
    Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
    Sidharta PN; Lindegger N; Ulč I; Dingemanse J
    J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
    Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
    Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
    Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.